Aerpio Pharmaceuticals, Inc. (27)

Browse by Contract Category

Contracts

License Agreement by and between Aadi Bioscience, Inc. and EOC Pharma (Hong Kong) Limited dated December 8, 2020 (Filed With SEC on November 10, 2021)
Employment Agreement dated October 19, 2021, by and between Loretta Itri and Aadi Bioscience, Inc (Filed With SEC on November 10, 2021)
First Amendment to Office Lease dated August 30, 2021 by and between BRE Sunset Coast, LLC and Aadi Bioscience, Inc (Filed With SEC on November 10, 2021)
Form of Indemnification Agreement between Aadi Bioscience, Inc. and each of its directors and executive officers (Filed With SEC on August 27, 2021)
2021 Employee Stock Purchase Plan (Filed With SEC on August 27, 2021)
Agreement and Plan of Merger, dated May 16, 2021, among Aerpio Pharmaceuticals, Inc., Aadi Bioscience, Inc. and Aspen Merger Subsidiary, Inc (Filed With SEC on May 17, 2021)
Description of Registrants Securities (Filed With SEC on March 16, 2020)
Amendment No. 1 to the Amended and Restated License Agreement between Abraxis BioScience, LLC and Aadi Bioscience, Inc (Filed With SEC on November 10, 2021)
Amended and Restated License Agreement by and between Abraxis BioScience, LLC and Aadi Bioscience, Inc. dated November 15, 2019 (Filed With SEC on November 10, 2021)
Employment Agreement dated September 14, 2021, by and between Brendan Delaney and the Company (Filed With SEC on September 20, 2021)
Consulting Agreement, dated July 20, 2021, by and between Aadi Bioscience, Inc. and Danforth Advisors, LLC (Filed With SEC on August 27, 2021)
Form of Stock Option Agreement under the Aadi Bioscience, Inc. 2014 Equity Incentive Plan (Filed With SEC on August 27, 2021)
Aadi Bioscience, Inc. 2014 Equity Incentive Plan (Filed With SEC on August 27, 2021)
Form of Stock Option Agreement under the Aadi Bioscience, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 27, 2021)
Aadi Bioscience, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 27, 2021)
Amended and Restated Employment Agreement, dated August 26, 2021, by and between Aadi Bioscience, Inc. and Neil Desai, Ph.D (Filed With SEC on August 27, 2021)
Registration Rights Agreement, dated August 26, 2021, by and between Aadi Bioscience, Inc. (formerly known as Aerpio Pharmaceuticals, Inc.) and certain purchasers listed therein (Filed With SEC on August 27, 2021)
Contingent Value Rights Agreement dated August 26, 2021, by and between Aerpio Pharmaceuticals, Inc., Cheryl Cohen, as Holder Representative, and American Stock Transfer & Trust... (Filed With SEC on August 27, 2021)
Asset Purchase Agreement dated August 17, 2021, by and between Aerpio Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc (Filed With SEC on August 23, 2021)
Subscription Agreement, dated May 16, 2021, by and among Aerpio Pharmaceuticals, Inc. and each purchaser identified on Exhibit A thereto (Filed With SEC on May 17, 2021)
Consulting Services Agreement, entered into on April 1, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin G. Peters (Filed With SEC on April 1, 2021)
Amendment to Transition Services Agreement, entered into on April 1, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin G. Peters (Filed With SEC on April 1, 2021)
Transition Services Agreement, entered into on February 9, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin Peters (Filed With SEC on February 16, 2021)
Amendment No. 2 to Employment Agreement, entered into on January 31, 2021, by and between Aerpio Pharmaceuticals, Inc. and Joseph Gardner (Filed With SEC on February 1, 2021)
Amendment No. 1 to License Agreement, dated May 11, 2020, by and between Aerpio Pharmaceuticals, Inc. and GB004, Inc (Filed With SEC on May 12, 2020)
Employment Agreement, dated November 6, 2019, by and between the Company and Regina Marek (Filed With SEC on November 7, 2019)
Offer Letter, dated July 15, 2018, by and between the Company and Gina Marek (Filed With SEC on October 18, 2019)